Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

2-Methoxyestradiol suppresses osteolytic breast cancer tumor progression in vivo.

Cicek M, Iwaniec UT, Goblirsch MJ, Vrabel A, Ruan M, Clohisy DR, Turner RR, Oursler MJ.

Cancer Res. 2007 Nov 1;67(21):10106-11.

2.
3.

The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.

Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, Myers D, Nakamura A, Waltham MC, Gillespie MT, Thompson EW.

Cancer Res. 2005 Jun 1;65(11):4929-38.

4.

Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.

Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR.

J Clin Invest. 1996 Oct 1;98(7):1544-9.

5.

Pharmacologic inhibitors of IkappaB kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo.

Idris AI, Libouban H, Nyangoga H, Landao-Bassonga E, Chappard D, Ralston SH.

Mol Cancer Ther. 2009 Aug;8(8):2339-47. doi: 10.1158/1535-7163.MCT-09-0133. Epub 2009 Aug 11.

6.

Transforming growth factor-beta signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation.

Futakuchi M, Nannuru KC, Varney ML, Sadanandam A, Nakao K, Asai K, Shirai T, Sato SY, Singh RK.

Cancer Sci. 2009 Jan;100(1):71-81. doi: 10.1111/j.1349-7006.2008.01012.x. Epub 2008 Nov 25.

7.

Estradiol enhances osteolytic lesions in mice inoculated with human estrogen receptor-negative MDA-231 breast cancer cells in vivo.

Winding B, Misander H, Høegh-Andersen P, Brünner N, Foged NT.

Breast Cancer Res Treat. 2003 Mar;78(2):205-16.

PMID:
12725420
8.

Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.

Wilson TJ, Nannuru KC, Futakuchi M, Sadanandam A, Singh RK.

Cancer Res. 2008 Jul 15;68(14):5803-11. doi: 10.1158/0008-5472.CAN-07-5889.

9.

Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma.

Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T.

Cancer. 2000 Jun 15;88(12 Suppl):2979-88. Review.

PMID:
10898341
10.

Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases.

Hussein O, Tiedemann K, Murshed M, Komarova SV.

Cancer Lett. 2012 Jan 28;314(2):176-84. doi: 10.1016/j.canlet.2011.09.026. Epub 2011 Sep 29.

PMID:
22014409
11.

Evidence that 2-methoxyestradiol suppresses proliferation and accelerates apoptosis in normal rat growth plate chondrocytes.

Sibonga JD, Sommer U, Turner RT.

J Cancer Res Clin Oncol. 2002 Sep;128(9):477-83. Epub 2002 Aug 21.

PMID:
12242511
12.

A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.

Le Gall C, Bellahcène A, Bonnelye E, Gasser JA, Castronovo V, Green J, Zimmermann J, Clézardin P.

Cancer Res. 2007 Oct 15;67(20):9894-902.

13.

Anti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murine models.

Hsu YH, Hsing CH, Li CF, Chan CH, Chang MC, Yan JJ, Chang MS.

J Immunol. 2012 Feb 15;188(4):1981-91. doi: 10.4049/jimmunol.1102843. Epub 2012 Jan 11.

14.

Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, Holen I.

J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78. doi: 10.1093/jnci/djn240. Epub 2008 Aug 11.

PMID:
18695136
15.

Effect of a V-ATPase inhibitor, FR202126, in syngeneic mouse model of experimental bone metastasis.

Niikura K.

Cancer Chemother Pharmacol. 2007 Sep;60(4):555-62. Epub 2006 Dec 23.

PMID:
17187252
16.

2-methoxyestradiol analogue ENMD-1198 reduces breast cancer-induced osteolysis and tumor burden both in vitro and in vivo.

Snoeks TJ, Mol IM, Que I, Kaijzel EL, Löwik CW.

Mol Cancer Ther. 2011 May;10(5):874-82. doi: 10.1158/1535-7163.MCT-10-0997. Epub 2011 Mar 21.

17.

Trolox inhibits osteolytic bone metastasis of breast cancer through both PGE2-dependent and independent mechanisms.

Lee JH, Kim B, Jin WJ, Kim JW, Kim HH, Ha H, Lee ZH.

Biochem Pharmacol. 2014 Sep 1;91(1):51-60. doi: 10.1016/j.bcp.2014.06.005. Epub 2014 Jun 11.

PMID:
24929117
18.

The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling.

Ling X, Konopleva M, Zeng Z, Ruvolo V, Stephens LC, Schober W, McQueen T, Dietrich M, Madden TL, Andreeff M.

Cancer Res. 2007 May 1;67(9):4210-8. Erratum in: Cancer Res. 2008 Jun 15;68(12):4958.

19.

Human breast cancer cells induced angiogenesis, recruitment, and activation of osteoclasts in osteolytic metastasis.

Winding B, Misander H, Sveigaard C, Therkildsen B, Jakobsen M, Overgaard T, Oursler MJ, Foged NT.

J Cancer Res Clin Oncol. 2000 Nov;126(11):631-40.

PMID:
11079727
20.

A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo.

Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC, Doñate F, Shaw DE, Mazar AP, Rabbani SA.

Mol Cancer Ther. 2006 Sep;5(9):2271-80.

Supplemental Content

Support Center